Filing Flows

Filing Flows › 8-K events › Curaleaf Holdings

Curaleaf Holdings: other events

Form 8-K filed Nov 5, 2026 · items 8.01

What the filing says

uncertainties and other factors, many of which are beyond Curaleaf's control, that could cause actual results to differ materially, including the response of Aurora and its board of directors to the Offer, the terms and outcome of the competing proposal, the satisfaction or waiver of the conditions of the Offer, the re

Read the filing on SEC EDGAR →

What usually followsAcross 44,881 8-Ks reporting Item 8.01 (other events) in our universe, the stock's median move the next session was +0.1% (typical size ±1.5%, up 52% of the time); over the following 21 sessions, +1.1%. Every item ranked →

Curaleaf Holdings at a glance

Latest quarterQ3 2026
Revenue$352.6M
Revenue Y/Y+11%
Operating margin0.8%
IndustryMedicinal Chemicals & Botanical Products

Curaleaf Holdings, Q3 2026: revenue $353M (+11% year over year), operating margin 0.8%. The chart follows the revenue to costs, profit and cash.

Curaleaf Holdings: every quarter, Q/Q and Y/Y, holders and guidance →

Curaleaf Holdings’s other material 8-Ks

Other recent mergers and acquisitions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.